Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold? - Wikidata - wikimedia - TriplyDB

Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?

Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?

http://www.wikidata.org/entity/Q35154540

about

AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations.

P2860

Q35925706-5AF4AB42-D1F3-49BB-9F1E-8A45905313D5 Q36035236-680CAD97-2DE4-468A-AECE-3C553DA5C9CB

P2860

Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?

http://www.wikidata.org/entity/Q35154540

description

2003 nî lūn-bûn

@nan

2003 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?

@ast

Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?

@en

type

label

Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?

@ast

Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?

@en

prefLabel

Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?

@ast

Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?

@en

P1433

Q35154540-D9330E7B-E753-44DF-BF74-5EAF626AB176

P1476

Q35154540-FD32D109-DA8E-4CD6-9319-6B379897595F

P2093

Q35154540-2D88B3AE-D00F-4C9C-8CB5-AA6EC82AF971

P2860

Q35154540-0E534EB3-5223-4E03-9EA5-4EC7CD62F739

Q35154540-12821F7C-BDEF-4394-B40B-A5772FCD2FFC

Q35154540-1CDF22B3-0196-40CB-8450-49B84732BD41

Q35154540-1DA2D0F6-0398-4C4D-9115-BE9BA120E7A7

Q35154540-1F4D8FBF-3CFF-4DF7-9485-75848FFB286B

Q35154540-219AC372-C473-450A-88D6-857D85F43769

Q35154540-26078392-C7F8-408B-B758-73B5DD5BB739

Q35154540-2D87ED75-A346-4EF7-9F8E-8BC764C4B6D7

Q35154540-2E4DFB72-4474-43DE-9493-AA4089918D8C

Q35154540-31CA557D-9561-49C0-9807-F86F0C2BF5CF

P304

Q35154540-2E5DE197-0B50-4249-8E92-914FBA19C515

P31

Q35154540-813555AB-854D-4A5E-8A56-538A851B4A33

P356

Q35154540-D8D36468-CAA5-4783-83A9-9F7C12FBA291

P433

Q35154540-A75B46E2-D089-4F7A-8632-166DC25886F2

P478

Q35154540-B7747B1E-8D36-48B0-BDEF-142F8FFEC912

P577

Q35154540-A407E876-E9A0-426B-8C59-1B359A72C63A

P5875

Q35154540-8156FB39-EF15-4FD9-AB8C-3F8D22D749F0

P698

Q35154540-8D56A90E-5F6B-48B3-9112-636EC2C5746B

P356

P1433

Journal of the Renin-Angiotensin-Aldosterone System

P1476

Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?

@en

P2093

Michael A Weber

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report

Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study--ELITE II

Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

P304

62-73

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3317/JRAAS.2003.015

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2003-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10707643

http://www.w3.org/2001/XMLSchema#string

P698

12806587

http://www.w3.org/2001/XMLSchema#string